- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Gov't: Average Monthly Premium for Medicare Drug Plans Will Rise by $1 for 2014, to $31
The Obama administration says the average monthly premium for Medicare prescription drug plans will inch up by $1 next year, to $31.
The Obama administration says the average monthly premium for Medicare prescription drug plans will inch up by $1 next year, to $31.
The increase comes after three stable years in which the average premium hovered around $30 a month.
Medicare officials say the modest increase means competition among insurers is holding down costs, even as benefits have improved for seniors with high prescription bills.
But consumers take note: the average isn’t the full story. For example, last year seven of the top 10 plans raised their 2013 premiums by double-digit percentages. By shopping around, seniors helped keep the average premium paid from going up.
Read the full story here: http://wapo.st/18Lpe96
Source: The Washington Post
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
